Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
作者信息
Eun Chang Soo
机构信息
Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea.
出版信息
Gut Liver. 2017 Jan 15;11(1):3-4. doi: 10.5009/gnl16574.
Abstract
摘要
相似文献
1
Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?韩国炎症性肠病患者是否需要进行抗TNF药物的治疗药物监测？
Gut Liver. 2017 Jan 15;11(1):3-4. doi: 10.5009/gnl16574.
2
Optimizing Therapeutic Drug Monitoring of Tumor Necrosis Factor-α Antagonists in Patients With Inflammatory Bowel Diseases.优化炎症性肠病患者肿瘤坏死因子-α拮抗剂的治疗药物监测
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1509. doi: 10.1016/j.cgh.2016.04.029. Epub 2016 May 2.
3
Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.抗 TNF-α 药物的作用机制分子 - 治疗性 TNF-α 拮抗剂的比较。
Cytokine. 2018 Jan;101:56-63. doi: 10.1016/j.cyto.2016.08.014. Epub 2016 Aug 24.
4
Pharmacokinetics of biologics and the role of therapeutic monitoring.生物制品的药代动力学及治疗药物监测的作用。
Gastroenterol Clin North Am. 2014 Sep;43(3):565-79. doi: 10.1016/j.gtc.2014.05.007. Epub 2014 Jun 24.
5
Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.通过监测药物水平和抗药抗体优化炎症性肠病中肿瘤坏死因子抑制剂的治疗
Inflamm Bowel Dis. 2016 Aug;22(8):1999-2015. doi: 10.1097/MIB.0000000000000772.
6
Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.抗TNF单克隆抗体在炎症性肠病中的药代动力学：为当前治疗增添价值。
J Clin Pharmacol. 2015 Mar;55 Suppl 3:S39-50. doi: 10.1002/jcph.374.
7
Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.对英夫利昔单抗无反应可能是由于先天性中和抗肿瘤坏死因子-α抗体。
Clin Exp Immunol. 2008 Dec;154(3):325-31. doi: 10.1111/j.1365-2249.2008.03773.x. Epub 2008 Sep 23.
8
Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.综述文章：炎症性肠病中抗TNF生物类似药的药理学方面
Aliment Pharmacol Ther. 2015 Nov;42(10):1158-69. doi: 10.1111/apt.13402. Epub 2015 Sep 13.
9
Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease.
Aliment Pharmacol Ther. 2018 Feb;47(3):436-437. doi: 10.1111/apt.14461.
10
Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.炎症性肠病患者抗TNF治疗的优化
Expert Rev Clin Pharmacol. 2016;9(3):429-39. doi: 10.1586/17512433.2016.1133288. Epub 2016 Jan 28.
引用本文的文献
1
Changing treatment paradigms for the management of inflammatory bowel disease.炎症性肠病治疗模式的转变
Korean J Intern Med. 2018 Jan;33(1):28-35. doi: 10.3904/kjim.2017.400. Epub 2017 Dec 28.
本文引用的文献
1
Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease.测量小儿炎症性肠病患者英夫利昔单抗谷浓度及抗体的临床应用
Gut Liver. 2017 Jan 15;11(1):55-61. doi: 10.5009/gnl16041.
2
Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID).硫嘌呤类药物在炎症性肠病中的应用：韩国肠道疾病研究协会（KASID）的共识声明
Intest Res. 2015 Jul;13(3):193-207. doi: 10.5217/ir.2015.13.3.193. Epub 2015 Jun 9.
3
Characteristics of Pediatric Inflammatory Bowel Disease in Korea: Comparison with EUROKIDS Data.韩国儿童炎症性肠病的特征：与欧洲儿童炎症性肠病（EUROKIDS）数据的比较
Gut Liver. 2015 Nov 23;9(6):756-60. doi: 10.5009/gnl14338.
4
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases.炎症性肠病中抗TNF-α药物的治疗药物监测
Expert Opin Biol Ther. 2015;15(8):1107-17. doi: 10.1517/14712598.2015.1044434. Epub 2015 May 7.
5
Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn's Disease with Infliximab Therapy.英夫利昔单抗治疗的儿童克罗恩病中TIM-3、人β-防御素-2和FOXP3的表达及其与疾病活动的相关性
Gut Liver. 2015 May 23;9(3):370-80. doi: 10.5009/gnl13408.
6
Tailoring anti-TNF therapy in IBD: drug levels and disease activity.在 IBD 中定制抗 TNF 治疗：药物水平与疾病活动度。
Nat Rev Gastroenterol Hepatol. 2014 Apr;11(4):243-55. doi: 10.1038/nrgastro.2013.253. Epub 2014 Jan 7.
7
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.综述文章：炎症性肠病中英夫利昔单抗治疗药物监测的临床医生指南。
Aliment Pharmacol Ther. 2013 Sep;38(5):447-59. doi: 10.1111/apt.12407. Epub 2013 Jul 14.
8
Optimizing anti-TNF treatments in inflammatory bowel disease.优化炎症性肠病的抗 TNF 治疗。
Autoimmun Rev. 2014 Jan;13(1):24-30. doi: 10.1016/j.autrev.2013.06.002. Epub 2013 Jun 19.
9
Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.克罗恩病中应答丧失和阿达木单抗剂量强化的需求：一项系统评价。
Am J Gastroenterol. 2011 Apr;106(4):674-84. doi: 10.1038/ajg.2011.60. Epub 2011 Mar 15.
Zotero 插件